151 related articles for article (PubMed ID: 36991394)
41. Cost-effectiveness analysis of vaccinating children in Malawi with RTS,S vaccines in comparison with long-lasting insecticide-treated nets.
Seo MK; Baker P; Ngo KN
Malar J; 2014 Feb; 13():66. PubMed ID: 24564883
[TBL] [Abstract][Full Text] [Related]
42. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.
Owusu-Agyei S; Ansong D; Asante K; Kwarteng Owusu S; Owusu R; Wireko Brobby NA; Dosoo D; Osei Akoto A; Osei-Kwakye K; Adjei EA; Boahen KO; Sylverken J; Adjei G; Sambian D; Apanga S; Kayan K; Vekemans J; Ofori-Anyinam O; Leach A; Lievens M; Demoitie MA; Dubois MC; Cohen J; Ballou WR; Savarese B; Chandramohan D; Gyapong JO; Milligan P; Antwi S; Agbenyega T; Greenwood B; Evans J
PLoS One; 2009 Oct; 4(10):e7302. PubMed ID: 19806184
[TBL] [Abstract][Full Text] [Related]
43. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
[TBL] [Abstract][Full Text] [Related]
44. Seasonal malaria vaccination: protocol of a phase 3 trial of seasonal vaccination with the RTS,S/AS01
Chandramohan D; Dicko A; Zongo I; Sagara I; Cairns M; Kuepfer I; Diarra M; Tapily A; Issiaka D; Sanogo K; Mahamar A; Sompougdou F; Yerbanga S; Thera I; Milligan P; Tinto H; Ofori-Anyinam O; Ouedraogo JB; Greenwood B
BMJ Open; 2020 Sep; 10(9):e035433. PubMed ID: 32933955
[TBL] [Abstract][Full Text] [Related]
45. Community perceptions on the secondary health benefits established by malaria vaccine trials (RTS,S phase 2 and phase 3) at the Korogwe site in North Eastern Tanzania.
Liheluka EA; Lusingu JP; Manongi RN
Malar J; 2013 May; 12():157. PubMed ID: 23651535
[TBL] [Abstract][Full Text] [Related]
46. Child malaria vaccine uptake in Ghana: Factors influencing parents' willingness to allow vaccination of their children under five (5) years.
Saaka SA; Mohammed K; K A Pienaah C; Luginaah I
PLoS One; 2024; 19(1):e0296934. PubMed ID: 38241404
[TBL] [Abstract][Full Text] [Related]
47. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
[TBL] [Abstract][Full Text] [Related]
48. Prevalence, determinants, and reasons for malaria vaccine hesitancy among caregivers of under-five children in Nigeria: Results from a nationwide cross-sectional survey.
Kabir Sulaiman S; Isma'il Tsiga-Ahmed F; Sale Musa M; Kabir Sulaiman A; Muhammad Dayyab F; Ab Khan M; Idris Ahmad S; Abasi-Okot Akpan U; Ibrahim Usman U; Tjjani Bako A
Vaccine; 2023 Feb; 41(8):1503-1512. PubMed ID: 36725434
[TBL] [Abstract][Full Text] [Related]
49. Pilot implementation of community health advocacy teams to improve the effectiveness of long-lasting insecticide net distribution through both campaigns and continuous channels in Ghana: a qualitative study of opportunities and barriers to implementation.
Dako-Gyeke P; Hornuvo R; Glozah FN; Asampong E; Tabong PT; Nwameme A; Chandi GM; Peprah NY; Gittelman D; Adongo PB
Front Public Health; 2023; 11():1133151. PubMed ID: 37583887
[TBL] [Abstract][Full Text] [Related]
50. The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries.
Sicuri E; Yaya Bocoum F; Nonvignon J; Alonso S; Fakih B; Bonsu G; Kariuki S; Leeuwenkamp O; Munguambe K; Mrisho M; Were V; Sauboin C
MDM Policy Pract; 2019; 4(2):2381468319896280. PubMed ID: 31903424
[No Abstract] [Full Text] [Related]
51. Outreach Training and Supportive Supervision for Quality Malaria Service Delivery: A Qualitative Evaluation in 11 Sub-Saharan African Countries.
Altaras R; Worges M; La Torre S; Audu BM; Mwangi G; Zeh-Meka A; Yikpotey P; Domkam Kammogne I; Chanda-Kapata P; Vanderick C; Yukich J; Streat E
Am J Trop Med Hyg; 2024 Mar; 110(3_Suppl):20-34. PubMed ID: 38320314
[TBL] [Abstract][Full Text] [Related]
52. Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.
Brooks A; Briët OJ; Hardy D; Steketee R; Smith TA
PLoS One; 2012; 7(3):e32587. PubMed ID: 22412892
[TBL] [Abstract][Full Text] [Related]
53. A systematic review and meta-analysis of the prevalence of caregiver acceptance of malaria vaccine for under-five children in low-income and middle-income countries (LMICs).
Sulaiman SK; Musa MS; Tsiga-Ahmed FI; Dayyab FM; Sulaiman AK; Bako AT
PLoS One; 2022; 17(12):e0278224. PubMed ID: 36455209
[TBL] [Abstract][Full Text] [Related]
54. An observational analysis of the impact of indoor residual spraying in Northern, Upper East, and Upper West Regions of Ghana: 2014 through 2017.
Gogue C; Wagman J; Tynuv K; Saibu A; Yihdego Y; Malm K; Mohamed W; Akplu W; Tagoe T; Ofosu A; Williams I; Asiedu S; Richardson J; Fornadel C; Slutsker L; Robertson M
Malar J; 2020 Jul; 19(1):242. PubMed ID: 32652994
[TBL] [Abstract][Full Text] [Related]
55. Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis.
Topazian HM; Schmit N; Gerard-Ursin I; Charles GD; Thompson H; Ghani AC; Winskill P
Vaccine; 2023 May; 41(20):3215-3223. PubMed ID: 37080831
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness and public health impact of RTS,S/AS01
Ndeketa L; Mategula D; Terlouw DJ; Bar-Zeev N; Sauboin CJ; Biernaux S
Wellcome Open Res; 2020; 5():260. PubMed ID: 34632084
[No Abstract] [Full Text] [Related]
57. Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial.
Valéa I; Adjei S; Usuf E; Traore O; Ansong D; Tinto H; Owusu Boateng H; Leach A; Mwinessobaonfou Some A; Buabeng P; Vekemans J; Nana LA; Kotey A; Vandoolaeghe P; Ouedraogo F; Sambian D; Lievens M; Tahita MC; Rettig T; Jongert E; Lompo P; Idriss A; Borys D; Ouedraogo S; Prempeh F; Habib MA; Schuerman L; Sorgho H; Agbenyega T
Hum Vaccin Immunother; 2018 Jun; 14(6):1489-1500. PubMed ID: 29630438
[TBL] [Abstract][Full Text] [Related]
58. Malaria vaccination in Africa: A mini-review of challenges and opportunities.
Olawade DB; Wada OZ; Ezeagu CN; Aderinto N; Balogun MA; Asaolu FT; David-Olawade AC
Medicine (Baltimore); 2024 Jun; 103(24):e38565. PubMed ID: 38875411
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of pilot implementation of seasonal malaria chemoprevention on morbidity in young children in Northern Sahelian Ghana.
Ansah PO; Ansah NA; Malm K; Awuni D; Peprah N; Dassah S; Yarig S; Manful C; Agbenyeri J; Awoonor-Williams J; Ofosu W; Oduro AR
Malar J; 2021 Nov; 20(1):440. PubMed ID: 34794431
[TBL] [Abstract][Full Text] [Related]
60. RTS,S/AS01
Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
